I already hold a host of FTSE 100 stocks. The index, while having a considerable weighting towards energy and resources, provides me with exposure to a wealth of blue-chips in many sectors.
Today, I’m looking for stocks that could benefit from profound demographic changes that we’re likely to experience over the coming decades. So what are these changes and which firms could benefit?
Demographic changes
We all know about ageing populations. This is particularly the case in Europe, the US and China. With age comes increasing risk of illness, and naturally, this creates demand for healthcare and treatments.
But there are also profound changes in working-age populations. Around the turn of the millennium, we saw positive changes in labour supply. Factors including China’s demographic boom and the opening up of Eastern Europe were key to this.
A positive supply of labour led to low levels of inflation, low interest rates and near constant economic growth, albeit with stagnant wage growth.
However, things are changing. Wage stagnation has triggered a wave of popularism, especially in Europe, and we’re no longer seeing growth in the labour market. In fact, the UK labour market is particularly tight with some 10m people economically inactive — that’s unsustainable and unaffordable.
Stocks to prosper
Naturally, I’m looking at pharmaceuticals and biotech. AstraZeneca is one such FTSE stock.
The British pharma giant has a monoclonal antibody drug in stage I trials that aims to target a toxin that impacts the build-up of plaque on the brain. Early trails of MEDI1814 suggests the treatment could be highly effective in slowing or preventing Alzheimer’s disease.
In the UK, the rate of dementia per 1,000 people is expected to reach 29.3 by 2050. That’s just above the OECD average of 29.1. The illness is likely to be most prevalent in Japan.
This stage I trial isn’t the only reason I’m interested in AstraZeneca. After all, drugs trials often fail. However, it has a huge portfolio of drugs, treatments and vaccines, many of which are geared towards the challenges of ageing populations. I’m currently looking for an attractive entry point to buy the medical giant.
I’m also looking to buy more GSK shares. GSK generated £29.3bn in revenues last year, a 13% increase over 2021 at constant exchange rates. After the split with Haleon, the company is already starting to look like a leaner and more focused medical giant. I’m aware of the risks associated with the Zantac legal cases. However, I think the risk is already priced in.
Robotics solution
Finally, I’m increasingly interested in Ocado, a firm I’ve paid little attention to in recent years. The company is more than just an online grocery retailer. It deploys advanced robotics and AI to maximise operational efficiency. The company has struggled to turn a profit in recent years — and this is a concern — but the robotics side of the business could be lucrative in the years to come.
With labour shortages, having a warehouse automation system can prove advantageous. Other leading retailers are now licensing Ocadoâs robotics solution for their logistics operations. I see this ‘solutions’ side of the business gaining momentum in the coming years, even if the retail segment continues to struggle.
The post 3 FTSE 100 stocks I’m buying for an era of demographic change! appeared first on The Motley Fool UK.
Don’t miss this top growth pick for the ‘cost of living crisis’
While the media raves about Google and Amazon, this lesser-known stock has quietly grown 880% – with a:
Greater than 20X increase in margins
Nearly 60% compounded revenue growth over 5 years – more than Apple, Amazon and Google!
A 3,000% earnings explosion
Of course, past performance is no guarantee of future results. However, we think it’s stronger now than ever before. Amazingly, you may never have heard of this company.
Yet there’s a 1-in-3 chance you’ve used one of its 250 brands. Many are household names with millions of monthly website visitors, and that often help consumers compare items, shop around and save.
Now, as the ‘cost of living crisis’ bites, we believe its influence could soar. And that might bring imminent new gains to investors who’re in position today. So please, don’t leave without your FREE report, ‘One Top Growth Stock from The Motley Fool’.
Claim your FREE copy now
More reading
The FTSE 100 companies offering the highest dividends
An uneven recovery: can I still find bargain stocks on the FTSE 100?
Iâm listening to Warren Buffett to find cheap UK shares
I’d put £66 a week into this high-yield property stock for £500 a year in passive income
Why soaring Rolls-Royce shares have further to rally!
James Fox has positions in GSK and Haleon Plc. The Motley Fool UK has recommended GSK, Haleon Plc, and Ocado Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.